The exact molecular functions of Polo-like kinase 1 (PLK1) in mitotic prophase are not fully understood. This study shows ...
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a strong buy.
SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback